Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
43 participants
INTERVENTIONAL
2018-09-13
2019-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Added Fruit Pomace Fiber, Juice, and Whole Fruit on Postprandial Glycemia
NCT04182971
Effect of Orange Pomace Fiber on Glycemic Response
NCT02962375
Postprandial Glycemia in Apple Products
NCT03846986
Acute Effects of Fruit Juices Consumption on Postprandial Glycemic Responses and Satiety
NCT06163937
The Impact of Fruit Juice, Fruit Juice With Pomace, or Whole Fruit on Glycemic Response
NCT04369716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A planned sample size of 52 will be enrolled into the study. This study will require one initial screening visit and 3 study visits. This study will take approximately 3-4 weeks per subject to complete.
The initial screening visit will take \~2 hours and provide subject with the informed consent document and determine subject eligibility through anthropometric measurements, body composition measurement, vital signs, fasting blood glucose test (finger prick), a vein access scale evaluation, online 24-hr diet recall, and completion of a survey relate to general eating, health, and exercise habits. For women, a pregnancy test will be conducted.
If willing and eligible to participate, subjects will be invited to participate in the study for 3 study days. Eligible subjects will be instructed to follow a relatively low polyphenolic diet for at least 1 week prior the beginning of the study and continue for the duration of the study.
Each Study Day visit will last about \~3 hours. The day before each of the 3 Study Day visits, subjects will be asked to consume the same dinner meal and record on a food record. At each Study Day visit, subjects will arrive at the clinic after fasting for 10 to 12 hours and in a well-hydrated and well-rested state.
Each study visit will require blood draws throughout the visit. After evaluation of subject's health status (via anthropometric, vital sign and blood glucose measurements and in-person interview), a Licensed health Care Professional will place a catheter in subject's arm for the purpose of multiple blood sample collections and take the initial blood draw in the fasting state. Subjects will be randomized to receive one of study products based on randomized treatment sequences for 3 study visits immediately after fasting blood draw.
Participants will come to the research site on 3 separate occasions separated by a washout period. On each occasion 2 fasting blood samples will be obtained at 5 min intervals (-5, 0 minute (min)). Subjects will then consume one of the 3 treatments. Further blood samples will be taken at 15, 25, 30, 35, 40, 45, 60, 75, 90, 105 and 120 min. Self-reported visual analog scales (VAS) will be used to measure subject hunger, fullness, desire to eat, and prospective food intake. After completion of all study procedures and data/sample collection for the day, the catheter will be removed and subjects will be evaluated for safety and/or discomfort/symptoms before leaving the study site. They will be given a take-home snack and given written instructions in preparation for the next visit. Study day visits will be scheduled at least 3 days apart but no more than 7 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Orange Juice1
100% orange juice
Orange Juice1
100% Orange Juice
Orange Juice2
100% Orange Juice with enzyme-treated orange pomace fiber
Orange Juice2
100% Orange Juice with enzyme-treated orange pomace fiber
Raw Orange
raw orange
Raw Orange
Raw Orange
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orange Juice1
100% Orange Juice
Orange Juice2
100% Orange Juice with enzyme-treated orange pomace fiber
Raw Orange
Raw Orange
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a BMI of 20.0-24.9 kg/m2, inclusive and weight ≥ 110 lb. at screening visit.
* Subject is willing to maintain his/her usual physical activity pattern throughout the study period.
* Subject is willing to follow study instructions including compliance with dietary restrictions, consumption of study beverage, and study visit schedule.
* Subject is judged to be in good health on the basis of the medical history.
* Subject is willing to abstain from alcohol consumption for 24 hours prior to study visit.
* Exercise to be maintained throughout study duration, including 3 days before study visit
* Subject is willing to maintain stable dose of current vitamins, minerals, supplements and medications not interfering with study outcomes, including birth control, throughout study duration.
* Subject understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator/s and is willing to complete study procedures
Exclusion Criteria
* Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) at the screening visit.
* Subject has had major trauma or a surgical event within 2 months of study visit 1.
* Subject has had a weight change ≥4.5 kg within 2 months of visit, taking weight loss drugs, or has had bariatric surgery or other weight reduction surgery (ie. liposuction, laser fat removal, etc)
* Subject has a history or presence of clinically important endocrine, cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary, or gastrointestinal disorders that, in the opinion of the Investigator, could interfere with the interpretation of the study results.
* Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
* Subject has a history of extreme dietary habits, as judged by the Investigator (e.g., Atkins diet, etc.).
* Subject has a history of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
* Subject has a known intolerance or sensitivity to any ingredients in the study products.
* Subject has used medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, hypoglycemic medications, and systemic corticosteroids 2 weeks prior to visit 1 and throughout the study.
* Subject taking systemic steroids, extreme alcohol use, or drug user.
* Subject has vein access score less than 7
* Subject is a female, who is pregnant, planning to be pregnant during the study period or lactating.
* Subject is a current smoker. Past smoker abstinence for less than 2 years.
* Subject has participated in any clinical trial within 30d prior to enrollment.
* No participation in another Sponsored protocol within 6 months prior to enrollment
20 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Nutrition Research Center, Illinois Institute of Technology
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Britt Burton-Freeman, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Illinois Institute of Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Nutrition Research Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB2018-083
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.